BDH2 and acute myeloid leukemia: In contrast to LCN2, BDH2 high expression is an independent poor prognostic factor in AML patients, with a pro-proliferative effect on AML cells and reduced sensitivity to chemotherapeutic agents (Yang et al., 2013a).